 |
| |
| Nov-16-18 | Resumed |
Piper Jaffray |
Overweight |
$15 |
|
| Aug-08-18 | Resumed |
JP Morgan |
Overweight |
$9 |
|
| Jul-17-18 | Upgrade |
BofA/Merrill |
Underperform → Neutral |
|
|
| Jun-22-18 | Initiated |
Seaport Global Securities |
Neutral |
|
|
| Jan-02-18 | Upgrade |
RBC Capital Mkts |
Sector Perform → Outperform |
|
|
| Dec-20-17 | Initiated |
Barclays |
Equal Weight |
$6 |
|
| Sep-15-17 | Initiated |
RBC Capital Mkts |
Sector Perform |
$6 |
|
| Sep-06-17 | Upgrade |
JP Morgan |
Neutral → Overweight |
|
|
| Sep-06-17 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Feb-16-17 | Initiated |
Ladenburg Thalmann |
Buy |
$11 |
|
| Aug-12-16 | Upgrade |
Piper Jaffray |
Neutral → Overweight |
|
|
| Aug-04-16 | Downgrade |
JMP Securities |
Mkt Outperform → Mkt Perform |
|
|
| Feb-09-16 | Reiterated |
FBR Capital |
Outperform |
$18 → $6 |
|
| Feb-09-16 | Downgrade |
Needham |
Buy → Hold |
|
|
| Feb-09-16 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Feb-09-16 | Downgrade |
Jefferies |
Buy → Hold |
|
|
| Feb-08-16 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
|
|
| Jan-06-16 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Nov-11-15 | Downgrade |
BofA/Merrill |
Neutral → Underperform |
|
|
| Oct-09-15 | Downgrade |
BofA/Merrill |
Buy → Neutral |
|
|
|
|
| Feb-15-19 02:00PM | The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings Benzinga |
| Feb-14-19 03:30PM | Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst Investor's Business Daily |
| Feb-12-19 07:20AM | Detailed Research: Economic Perspectives on Callon Petroleum, Summit Materials, Echo Global Logistics, BioCryst Pharmaceuticals, NEXEO SOLUTIONS, and NL Industries What Drives Growth in Today's Competitive Landscape GlobeNewswire |
| Feb-06-19 03:10PM | How CEO Stonehouse is building up BioCryst's war chest to finance trials, drug launch American City Business Journals |
| 07:00AM | BioCryst Strengthens Cash Position With Flexible $100 Million Debt Facility GlobeNewswire |
| Feb-05-19 07:00AM | BioCryst to Present ZENITH-1 Results at American Academy of Allergy, Asthma & Immunology Annual Meeting GlobeNewswire +6.21% |
| Jan-04-19 07:00AM | BioCryst Appoints Steve Aselage to Board of Directors GlobeNewswire +5.51% |
| Jan-02-19 07:00AM | BioCryst to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.33% |
| 07:00AM | BioCryst Initiates Phase 1 Clinical Trial of Galidesivir GlobeNewswire |
| Dec-27-18 09:23AM | Stocks down in December for pharma firms in the Triangle American City Business Journals |
| Dec-17-18 06:42PM | Edited Transcript of BCRX earnings conference call or presentation 6-Nov-18 1:30pm GMT Thomson Reuters StreetEvents |
| Dec-16-18 09:13AM | BioCryst Pharmaceuticals, Inc. (BCRX) Hedge Funds Are Snapping Up Insider Monkey |
| Nov-27-18 08:55AM | New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| Nov-20-18 07:00AM | BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors GlobeNewswire +5.97% |
| Nov-16-18 07:00AM | BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology GlobeNewswire +7.66% |
| Nov-08-18 07:00AM | BioCryst to Present at Upcoming Investor Conferences GlobeNewswire |
| Nov-06-18 08:30AM | BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates Zacks |
| 07:27AM | BioCryst: 3Q Earnings Snapshot Associated Press |
| 07:00AM | BioCryst Reports Third Quarter 2018 Financial Results GlobeNewswire |
| Nov-05-18 07:00AM | BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology GlobeNewswire |
| Oct-30-18 10:33AM | Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q3 Earnings Expected to Decline Zacks |
| Oct-23-18 04:15PM | BioCryst to Report Third Quarter 2018 Financial Results on November 6 GlobeNewswire |
| Oct-16-18 07:50AM | Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire |
| Oct-12-18 09:17AM | Grifols (GRFS) Surges: Stock Moves 5.4% Higher Zacks +5.73% |
| Sep-25-18 04:15PM | BioCryst Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire |
| Sep-17-18 07:00AM | BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever GlobeNewswire |
| Sep-10-18 12:36PM | Here's Why BioCryst Pharmaceuticals Rose 21.3% in August Motley Fool |
| Sep-06-18 01:45PM | RTP pharma scores $35M contract to supply CDC American City Business Journals |
| 07:37AM | BioCryst stock surges 6% premarket after winning $35 million CDC contract for flu therapy MarketWatch |
| 07:00AM | CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile GlobeNewswire |
| Sep-05-18 08:28AM | The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga +5.27% |
| Sep-04-18 02:38PM | Inside The List: Highest-Paid Public Company CEOs American City Business Journals +6.01% |
| 12:15PM | CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks GlobeNewswire |
| 07:00AM | BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks GlobeNewswire |
| Aug-29-18 07:00AM | BioCryst Pharmaceuticals to Present at the Baird Global Healthcare Conference GlobeNewswire |
| Aug-20-18 01:50PM | Edited Transcript of BCRX earnings conference call or presentation 7-Aug-18 3:00pm GMT Thomson Reuters StreetEvents |
| Aug-15-18 08:00AM | New Research Coverage Highlights Cincinnati Bell, BioCryst Pharmaceuticals, Shutterstock, Kopin, Lands' End, and Pieris Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| Aug-07-18 03:38PM | BioCryst banks gross proceeds of $57.5M from offering American City Business Journals |
| 07:30AM | BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates Zacks |
| 06:05AM | BioCryst: 2Q Earnings Snapshot Associated Press |
| 06:00AM | BioCryst Reports Second Quarter 2018 Financial Results GlobeNewswire |
| Aug-06-18 04:01PM | BioCryst Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Completion of Public Offering of Common Stock GlobeNewswire |
| 02:18PM | BioCryst gets FDA nod on key drug American City Business Journals |
| 06:00AM | U.S. FDA Grants Fast Track Designation for BioCrysts BCX7353 GlobeNewswire |
| Aug-02-18 04:13PM | After Idera deal called off, BioCryst looks to raise $50M American City Business Journals +9.96% |
| 02:40PM | Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today Motley Fool |
| 08:54AM | The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter Benzinga |
| Aug-01-18 09:59PM | BioCryst Pharmaceuticals Prices Public Offering of Common Stock GlobeNewswire -6.44% |
| 04:01PM | BioCryst Pharmaceuticals Commences Public Offering of Common Stock GlobeNewswire |
| Jul-27-18 09:00AM | BioCryst to Announce Second Quarter 2018 Financial Results on August 7 GlobeNewswire |
| Jul-25-18 06:00PM | BioCryst Announces Publication of APeX-1 Clinical Trial Results for BCX7353 in The New England Journal of Medicine GlobeNewswire |
| Jul-24-18 07:30AM | Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks ACCESSWIRE |
| Jul-17-18 08:37AM | Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4 Benzinga |
| Jul-11-18 05:33PM | Why American Airlines, Idera Pharmaceuticals, and RH Holdings Slumped Today Motley Fool |
| 02:34PM | Why Idera Pharmaceuticals Is Sinking Today Motley Fool |
| 01:26PM | Spurned at the altar: BioCryst shareholders reject merger with Exton's Idera Pharmaceuticals American City Business Journals |
| 11:56AM | Future of Idera's Cambridge office uncertain after failed merger American City Business Journals |
| 09:23AM | Stocks to Watch: Boeing, Ford, American Airlines, JetBlue, Pfizer, Comcast, Alphabet, Nvidia, AbbVie The Wall Street Journal |
| 08:15AM | Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares Benzinga |
| 08:00AM | BioCryst Provides Update on Strategy, Pipeline and Outlook Business Wire |
| Jul-10-18 06:00PM | No deal: BioCryst shareholders thwart merger with Idera American City Business Journals |
| 05:36PM | [$$] Idera Pharmaceuticals and BioCryst Pharmaceuticals Terminate Merger Plans The Wall Street Journal |
| 04:35PM | BioCryst's stock jumps, Idera drops as proposed merger called off MarketWatch |
| 04:01PM | BioCryst Pharmaceuticals Announces Termination of Merger Agreement with Idera Pharmaceuticals Business Wire |
| Jun-25-18 07:15AM | Free Pre-Market Technical Pulse on AVEO Pharma and Three More Biotech Stocks ACCESSWIRE |
| 06:00AM | BioCryst Reports Agreement with PMDA on Phase 3 Clinical Trial and Regulatory Requirements for Marketing Authorization of BCX7353 in Japan GlobeNewswire |
| Jun-20-18 04:20PM | Great Point Partners, LLC Remains Opposed To The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. PR Newswire |
| Jun-13-18 10:28AM | Idera Stock Down, Study on Dermatomyositis Candidate Fails Zacks |
| 07:00AM | BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference GlobeNewswire |
| Jun-05-18 07:30AM | BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera Business Wire |
| May-29-18 08:00AM | BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress GlobeNewswire |
| May-24-18 12:30PM | BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema GlobeNewswire |
| 06:00AM | BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire |
| May-17-18 09:00AM | Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks ACCESSWIRE |
| May-14-18 09:51AM | Edited Transcript of BCRX earnings conference call or presentation 8-May-18 3:00pm GMT Thomson Reuters StreetEvents +9.27% |
| May-10-18 07:05AM | Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient ACCESSWIRE |
| May-08-18 10:11AM | Will BioCryst Pharmaceuticals Incs (NASDAQ:BCRX) Earnings Grow In The Years Ahead? Simply Wall St. -9.53% |
| 09:37AM | BioCryst: 1Q Earnings Snapshot Associated Press |
| 06:00AM | BioCryst Reports First Quarter 2018 Financial Results GlobeNewswire |
| May-02-18 08:24AM | BioCryst lands European approval for flu treatment American City Business Journals +5.94% |
| May-01-18 06:00AM | BioCryst Receives European Medicines Agency Approval for ALPIVAB for the Treatment of Influenza GlobeNewswire |
| Apr-26-18 08:20AM | New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals, and Trevena Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire |
| 06:00AM | BioCryst to Announce First Quarter 2018 Financial Results on May 8 GlobeNewswire |
| Apr-10-18 02:51PM | Vote on proposed merger of biopharm firms pushed back American City Business Journals |
| 07:30AM | BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger Business Wire |
| Apr-03-18 02:38PM | Why another BioCryst shareholder plans to vote against Idera merger American City Business Journals +5.86% |
| Apr-02-18 08:13AM | RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals PR Newswire |
| 08:00AM | BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals Business Wire |
| Mar-29-18 05:21AM | Edited Transcript of BCRX earnings conference call or presentation 27-Feb-18 4:00pm GMT Thomson Reuters StreetEvents |
| Mar-26-18 04:05PM | Eyenovia Appoints Three Industry Veterans to Board of Directors GlobeNewswire |
| Mar-23-18 11:00PM | Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals, Inc. (BCRX) GlobeNewswire |
| Mar-22-18 12:00PM | BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference GlobeNewswire |
| Mar-20-18 02:58PM | 15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies TheStreet.com |
| Mar-15-18 06:00AM | BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema GlobeNewswire |
| Mar-09-18 07:50AM | Blog Exposure - Esperion Therapeutics Reported Positive Top-line Results from First Pivotal Phase-3 Study of its Cholestrol Drug, Bempedoic Acid ACCESSWIRE |
| Feb-28-18 06:00AM | BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema GlobeNewswire |
| Feb-27-18 09:35AM | Does BioCryst Pharmaceuticals Incs (NASDAQ:BCRX) Earnings Growth Make It An Outperformer? Simply Wall St. |
| 09:31AM | BioCryst reports 4Q loss Associated Press |
| 08:30AM | BioCryst Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire |
| 08:00AM | BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger GlobeNewswire |
|
|
|
|
| BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Powell Lynne | Senior VP - CCO | Jan 28 | Option Exercise | 3.22 | 6,000 | 19,320 | 4,000 | Jan 29 04:21 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Jan 28 | Option Exercise | 5.45 | 5,000 | 27,250 | 133,426 | Jan 30 04:10 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Jan 28 | Sale | 9.85 | 5,000 | 49,250 | 128,426 | Jan 30 04:10 PM | | Powell Lynne | Senior VP - CCO | Jan 28 | Sale | 9.89 | 6,000 | 59,340 | 0 | Jan 29 04:21 PM | | Powell Lynne | Senior VP - CCO | Jan 25 | Option Exercise | 3.22 | 6,000 | 19,320 | 6,000 | Jan 29 04:21 PM | | Powell Lynne | Senior VP - CCO | Jan 25 | Sale | 9.60 | 6,000 | 57,600 | 0 | Jan 29 04:21 PM | | Powell Lynne | Senior VP - CCO | Jan 18 | Option Exercise | 3.22 | 2,000 | 6,440 | 2,000 | Jan 23 04:12 PM | | Powell Lynne | Senior VP - CCO | Jan 18 | Sale | 9.40 | 2,000 | 18,800 | 0 | Jan 23 04:12 PM | | Powell Lynne | Senior VP - CCO | Jan 16 | Option Exercise | 3.22 | 3,046 | 9,808 | 3,046 | Jan 18 04:03 PM | | Powell Lynne | Senior VP - CCO | Jan 16 | Sale | 9.27 | 3,046 | 28,236 | 0 | Jan 18 04:03 PM | | Powell Lynne | Senior VP - CCO | Jan 14 | Option Exercise | 3.22 | 954 | 3,072 | 954 | Jan 16 04:24 PM | | Powell Lynne | Senior VP - CCO | Jan 14 | Sale | 9.20 | 954 | 8,777 | 0 | Jan 16 04:24 PM | | Sheridan William P | Senior VP - CMO | Dec 18 | Sale | 7.58 | 20,488 | 155,299 | 2,725 | Dec 20 04:37 PM | | Powell Lynne | Senior VP - CCO | Dec 10 | Option Exercise | 3.22 | 4,000 | 12,880 | 2,000 | Dec 12 04:13 PM | | Powell Lynne | Senior VP - CCO | Dec 10 | Sale | 9.06 | 4,000 | 36,240 | 0 | Dec 12 04:13 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Dec 04 | Sale | 9.45 | 3,922 | 37,063 | 133,461 | Dec 06 04:30 PM | | Stonehouse Jon P | President & CEO | Dec 03 | Option Exercise | 1.20 | 80,000 | 96,000 | 807,674 | Dec 06 04:34 PM | | Stonehouse Jon P | President & CEO | Dec 03 | Sale | 9.12 | 80,000 | 729,600 | 727,674 | Dec 06 04:34 PM | | Barnes Alane P | Senior VP, Chief Legal Officer | Nov 30 | Option Exercise | 1.42 | 25,000 | 35,500 | 122,243 | Dec 04 04:11 PM | | Barnes Alane P | Senior VP, Chief Legal Officer | Nov 30 | Sale | 9.07 | 44,290 | 401,710 | 77,953 | Dec 04 04:11 PM | | Erck Stanley C | Director | Nov 28 | Option Exercise | 1.49 | 8,333 | 12,416 | 48,333 | Nov 30 04:02 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 23 | Option Exercise | 3.78 | 3,500 | 13,230 | 140,883 | Nov 26 04:19 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 23 | Sale | 9.66 | 3,500 | 33,810 | 137,383 | Nov 26 04:19 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 21 | Option Exercise | 4.48 | 12,000 | 53,710 | 144,383 | Nov 26 04:19 PM | | Powell Lynne | Senior VP - CCO | Nov 21 | Option Exercise | 3.22 | 12,000 | 38,640 | 14,455 | Nov 26 04:22 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 21 | Sale | 9.22 | 12,000 | 110,610 | 137,383 | Nov 26 04:19 PM | | Powell Lynne | Senior VP - CCO | Nov 21 | Sale | 9.05 | 14,455 | 130,840 | 0 | Nov 26 04:22 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 20 | Option Exercise | 3.45 | 11,123 | 38,405 | 143,883 | Nov 21 04:48 PM | | Powell Lynne | Senior VP - CCO | Nov 20 | Option Exercise | 3.22 | 9,127 | 29,389 | 17,732 | Nov 21 04:51 PM | | Powell Lynne | Senior VP - CCO | Nov 20 | Sale | 8.56 | 15,277 | 130,714 | 2,455 | Nov 21 04:51 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 20 | Sale | 8.68 | 11,123 | 96,494 | 137,383 | Nov 21 04:48 PM | | Powell Lynne | Senior VP - CCO | Nov 19 | Option Exercise | 3.22 | 193 | 621 | 8,798 | Nov 21 04:51 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 19 | Option Exercise | 3.78 | 75 | 284 | 137,458 | Nov 21 04:48 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 19 | Sale | 8.30 | 75 | 623 | 137,383 | Nov 21 04:48 PM | | Powell Lynne | Senior VP - CCO | Nov 19 | Sale | 8.30 | 193 | 1,602 | 8,605 | Nov 21 04:51 PM | | Powell Lynne | Senior VP - CCO | Nov 08 | Option Exercise | 3.22 | 5,280 | 17,002 | 13,885 | Nov 09 04:11 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 08 | Option Exercise | 3.32 | 13,415 | 44,485 | 148,496 | Nov 09 04:14 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 08 | Sale | 8.13 | 13,415 | 109,011 | 137,383 | Nov 09 04:14 PM | | Powell Lynne | Senior VP - CCO | Nov 08 | Sale | 8.15 | 5,280 | 43,032 | 8,605 | Nov 09 04:11 PM | | Powell Lynne | Senior VP - CCO | Nov 07 | Option Exercise | 3.22 | 300 | 966 | 8,905 | Nov 09 04:11 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 07 | Option Exercise | 3.22 | 672 | 2,164 | 138,055 | Nov 09 04:14 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 07 | Sale | 8.00 | 672 | 5,376 | 137,383 | Nov 09 04:14 PM | | Powell Lynne | Senior VP - CCO | Nov 07 | Sale | 8.00 | 300 | 2,400 | 8,605 | Nov 09 04:11 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 05 | Option Exercise | 3.22 | 215 | 692 | 137,598 | Nov 07 04:03 PM | | Powell Lynne | Senior VP - CCO | Nov 05 | Option Exercise | 3.22 | 100 | 322 | 8,705 | Nov 07 04:05 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 05 | Sale | 8.00 | 215 | 1,720 | 137,383 | Nov 07 04:03 PM | | Powell Lynne | Senior VP - CCO | Nov 05 | Sale | 8.00 | 100 | 800 | 8,605 | Nov 07 04:05 PM | | Powell Lynne | Senior VP - CCO | Nov 02 | Option Exercise | 3.22 | 1,000 | 3,220 | 9,605 | Nov 06 04:07 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 02 | Option Exercise | 3.40 | 10,856 | 36,916 | 144,739 | Nov 06 04:04 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Nov 02 | Sale | 7.84 | 10,856 | 85,090 | 137,383 | Nov 06 04:04 PM | | Powell Lynne | Senior VP - CCO | Nov 02 | Sale | 8.00 | 1,000 | 8,000 | 8,605 | Nov 06 04:07 PM | | Powell Lynne | Senior VP - CCO | Nov 01 | Sale | 7.51 | 1,544 | 11,595 | 8,605 | Nov 05 01:17 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Oct 19 | Option Exercise | 3.78 | 3,150 | 11,907 | 140,533 | Oct 23 01:34 PM | | Powell Lynne | Senior VP - CCO | Oct 19 | Sale | 7.50 | 100 | 750 | 10,149 | Oct 23 01:31 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Oct 19 | Sale | 7.45 | 3,150 | 23,468 | 137,383 | Oct 23 01:34 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Oct 03 | Option Exercise | 3.27 | 1,072 | 3,508 | 138,355 | Oct 04 01:09 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Oct 03 | Sale | 7.28 | 1,072 | 7,802 | 137,383 | Oct 04 01:09 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Oct 02 | Option Exercise | 3.43 | 8,778 | 30,085 | 142,911 | Oct 04 01:09 PM | | STAAB THOMAS R II | Senior Vice President and CFO | Oct 02 | Sale | 7.24 | 8,778 | 63,556 | 137,383 | Oct 04 01:09 PM | | Sheridan William P | Senior VP - CMO | Aug 09 | Option Exercise | 1.42 | 62,500 | 88,750 | 85,713 | Aug 13 10:07 AM | | Sheridan William P | Senior VP - CMO | Aug 09 | Sale | 7.03 | 62,500 | 439,375 | 23,213 | Aug 13 10:07 AM | | Sheridan William P | Senior VP - CMO | Jun 01 | Option Exercise | 2.58 | 42,112 | 108,649 | 63,170 | Jun 05 03:07 PM | | Sheridan William P | Senior VP - CMO | Jun 01 | Sale | 6.30 | 42,112 | 265,306 | 21,058 | Jun 05 03:07 PM | | Stonehouse Jon P | President & CEO | May 17 | Option Exercise | 1.42 | 70,427 | 100,006 | 725,519 | May 21 09:31 AM | | Barnes Alane P | VP, General Counsel & Corp Sec | May 15 | Option Exercise | 1.42 | 12,500 | 17,750 | 98,268 | May 17 09:25 AM | | Babu Yarlagadda S | Senior VP - Drug Discovery | Mar 06 | Option Exercise | 3.26 | 30,000 | 97,800 | 120,618 | Mar 08 03:48 PM | | Barnes Alane P | VP, General Counsel & Corp Sec | Feb 28 | Option Exercise | 3.26 | 6,709 | 21,871 | 85,768 | Mar 02 02:21 PM | | Stonehouse Jon P | President & CEO | Feb 28 | Option Exercise | 3.26 | 56,949 | 185,654 | 698,316 | Mar 02 02:23 PM |
|
|
|
|
|
|
